Different positioning of the ligand-binding domain helix 12 and the F domain of the estrogen receptor accounts for functional differences between agonists and antagonists.

Different positioning of the ligand-binding domain helix 12 and the F domain of the estrogen receptor accounts for functional differences between agonists and antagonists.

Item
http://www.wikidata.org/entity/Q33888199
Identification of a new hormone-binding site on the surface of thyroid hormone receptorJAB1 interacts with both the progesterone receptor and SRC-1Inhibitory cross-talk between estrogen receptor (ER) and constitutively activated androstane receptor (CAR). CAR inhibits ER-mediated signaling pathway by squelching p160 coactivatorsIdentification of an allosteric binding site for RORγt inhibition.Identification of four novel phosphorylation sites in estrogen receptor alpha: impact on receptor-dependent gene expression and phosphorylation by protein kinase CK2.Estrogen receptor-alpha 36 mediates mitogenic antiestrogen signaling in ER-negative breast cancer cells.Directed evolution of ligand dependence: small-molecule-activated protein splicing.Fate and removal of estrogens in municipal wastewater.Mutations targeted to a predicted helix in the extreme carboxyl-terminal region of the human estrogen receptor-alpha alter its response to estradiol and 4-hydroxytamoxifen.Unique protein determinants of the subtype-selective ligand responses of the estrogen receptors (ERalpha and ERbeta ) at AP-1 sites.Multiple roles of ligand in transforming the dioxin receptor to an active basic helix-loop-helix/PAS transcription factor complex with the nuclear protein Arnt.Conservative mutageneic perturbations of amino acids connecting helix 12 in the 1alpha,25(OH)2-D3 receptor (VDR) to the ligand cause significant transactivational effects.Unique functional properties of a member of the Fushi Tarazu-Factor 1 family from Schistosoma mansoni.The activity of the activation function 2 of the human hepatocyte nuclear factor 4 (HNF-4alpha) is differently modulated by F domains from various origins.Perspectives on designs of antiandrogens for prostate cancer.Differences in immunoreactivity of estrogen receptor (ER) in tamoxifen-sensitive and -resistant breast carcinomas: preclinical and first clinical investigations.
P2860

Different positioning of the ligand-binding domain helix 12 and the F domain of the estrogen receptor accounts for functional differences between agonists and antagonists.

Item
http://www.wikidata.org/entity/Q33888199
description
1998 nî lūn-bûn
@nan
1998 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Different positioning of the l ...... ween agonists and antagonists.
@ast
Different positioning of the l ...... ween agonists and antagonists.
@en
type
label
Different positioning of the l ...... ween agonists and antagonists.
@ast
Different positioning of the l ...... ween agonists and antagonists.
@en
prefLabel
Different positioning of the l ...... ween agonists and antagonists.
@ast
Different positioning of the l ...... ween agonists and antagonists.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P5875
P698
P921
P932
P356
P1433
P1476
Different positioning of the l ...... ween agonists and antagonists.
@en
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P5875
P698
P921
P932